Loading company…
Satsuma Pharmaceuticals develops STS101, an intranasal migraine drug combining dihydroergotamine with a nasal delivery device.
STS101 is evaluated in Phase 3 clinical trials for the acute treatment of migraine. Based in California, US, the company was founded in 2016 by President and CEO John Kollins and is traded on NASDAQ under STSA, with 21 employees. In April 2019 it raised USD 62 million in Series B funding led by Wellington Management Company, with participation from Osage University Partners, CAM Capital, Surveyor, Eventide Asset Management, Cormorant, Lumira Ventures and SBI Investment.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in